GEN İlaç ve Sağlık Ürünleri A.Ş.

Privately held: no public share price · Turkey

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
Glucocorticoid receptor (classical corticosteroid) + keratolytic agentsSmall molecule
Psoriasis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

25 September 2024Topline resultGN-037GN-037 Phase 2 (NCT05706870) met its primary endpoint (IGA treatment success at week 4)
GEN Pharmaceuticals · Source ↗

Financial reports

No financial reports recorded.